Table 2.
Overall survival |
|||
---|---|---|---|
Clinicopathological parameter | Relative risk | 95% Confidence interval | P |
Age, years | |||
<60 versus ≥60 | 1.331 | 0.742–2.389 | 0.338 |
Sex | |||
Female versus male | 1.478 | 0.814–2.684 | 0.200 |
Tumor stage | |||
T1–T2 versus T3–T4 | 0.042 | 0.001–3.071 | 0.148 |
Nodal stage | |||
N0 versus N1–3 | 0.572 | 0.242–1.351 | 0.203 |
Tumor metastasis | |||
M0 versus M1 | 0.168 | 0.091–0.308 | <0.001 |
TNM stage | |||
I, II versus III, IV | 0.107 | 0.015–0.774 | 0.027 |
Tumor grade (differentiation) | |||
Well versus moderate, poor | 0.515 | 0.125–2.125 | 0.359 |
CEA (5 ng/mL cutoff) | |||
Low versus high | 0.531 | 0.294–0.961 | 0.036 |
PLSCR1 expression | |||
Low versus high | 0.438 | 0.306–0.552 | 0.047 |